Overview

A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Status:
Not yet recruiting

Trial end date:
2025-03-14

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen